TY - JOUR T1 - Concurrent Chemoradiotherapy with Paclitaxel and Cisplatin for Adenocarcinoma of the Cervix JF - Anticancer Research JO - Anticancer Res SP - 1475 LP - 1479 VL - 32 IS - 4 AU - YUTAKA NAGAI AU - TAKAFUMI TOITA AU - AKIHIKO WAKAYAMA AU - TOMOKO NAKAMOTO AU - TAKUMA OOYAMA AU - AKEMI TOKURA AU - MORIHIKO INAMINE AU - WATARU KUDAKA AU - SADAYUKI MURAYAMA AU - YOICHI AOKI Y1 - 2012/04/01 UR - http://ar.iiarjournals.org/content/32/4/1475.abstract N2 - Background: It is unclear whether cisplatin-based concurrent chemoradiotherapy (CCRT) has the same effect on adenocarcinoma as on squamous cell carcinoma. Patients and Methods: We retrospectively analyzed data for 32 patients with stage IIB–IVA cervical adenocarcinoma who were treated with radiotherapy (RT) or CCRT. Fourteen patients were treated with RT, 8 with CCRT using cisplatin alone (CCRT-P), and 10 with CCRT using cisplatin plus paclitaxel (CCRT-TP). Results: Complete response was achieved in 7/14 patients in the RT group, 4/8 patients in the CCRT-P group, and 9/10 patients in the CCRT-TP group. Ten out of the 14 patients in the RT, 7/8 patients in the CCRT-P, and 2/10 patients in the CCRT-TP groups experienced locoregional recurrence. The 5-year overall survival rate in the RT, CCRT-P, and CCRT-TP groups was 7.1%, 25.0%, and 74.1%, respectively (p=0.0094). Conclusion: The present study demonstrated that CCRT-TP achieved much better local control for adenocarcinoma of the cervix, leading to a decrease in locoregional recurrence. ER -